Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.

Saved in:
Bibliographic Details
Title: Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Authors: Denkinger CM; Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany. Claudia.Denkinger@uni-heidelberg.de.; Partner site Heidelberg University Hospital, German Center for Infection Research, Heidelberg, Germany. Claudia.Denkinger@uni-heidelberg.de., Janssen M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Schäkel U; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Gall J; NCT Trial Center, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany., Leo A; Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany., Stelmach P; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Weber SF; Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany., Krisam J; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany., Baumann L; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany., Stermann J; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany., Merle U; Department of Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany., Weigand MA; Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany., Nusshag C; Department of Nephrology, University of Heidelberg, Heidelberg, Germany., Bullinger L; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Schrezenmeier JF; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital Dresden and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany., Alakel N; Department of Internal Medicine I, University Hospital Dresden and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany., Witzke O; Department of Infectious Diseases, West German Centre for Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Wolf T; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany., Vehreschild MJGT; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany., Schmiedel S; Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Addo MM; Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Partner site Hamburg-Lübeck-Borstel-Riems, German Center for Infection Research, Hamburg, Germany.; University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development, Hamburg, Germany., Herth F; Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany., Kreuter M; Center for Interstitial and Rare Lung Diseases, Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany., Tepasse PR; Department of Medicine B, Gastroenterology and Hepatology, University Hospital Münster, Münster, Germany., Hertenstein B; Medical Department I, Klinikum Bremen-Mitte, Bremen, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Morgner A; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Kiehl M; Department of Internal Medicine I, Frankfurt (Oder) General Hospital, Frankfurt (Oder), Germany., Hopfer O; Department of Internal Medicine I, Frankfurt (Oder) General Hospital, Frankfurt (Oder), Germany., Wattad MA; Department of Hematology, Oncology, Palliative Care and Stem Cell Transplantation, Klinikum Hochsauerland, Meschede, Germany., Schimanski CC; Department of Internal Medicine II, Klinikum Darmstadt, Darmstadt, Germany., Celik C; Department of Internal Medicine II, Klinikum Darmstadt, Darmstadt, Germany., Pohle T; Department of Internal Medicine I, Klinikum Herford, Herford, Germany., Ruhe M; Department of Internal Medicine I, Klinikum Herford, Herford, Germany., Kern WV; Department of Medicine II, Division of Infectious Diseases and Travel Medicine, University Medical Centre Freiburg, Freiburg, Germany., Schmitt A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Lorenz HM; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Souto-Carneiro M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Gaeddert M; Division of Infectious Disease and Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany., Halama N; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Department of Translational Immunotherapy (D240), German Cancer Research Center, Heidelberg, Germany.; Helmholtz Institute for Translational Oncology, Mainz, Germany., Meuer S; Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany., Kräusslich HG; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany., Müller B; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany., Schnitzler P; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany., Parthé S; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany., Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany., Gronkowski M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Klemmer J; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Schmitt M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Dreger P; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Kriegsmann K; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; NCT Trial Center, National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.; National Center for Tumor Diseases, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.
Source: Nature cancer [Nat Cancer] 2023 Jan; Vol. 4 (1), pp. 96-107. Date of Electronic Publication: 2022 Dec 29.
Publication Type: Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2662-1347
DOI:10.1038/s43018-022-00503-w